Cogstate's Total Assets for the quarter that ended in Dec. 2025 was €58.08 Mil.
During the past 12 months, Cogstate's average Total Assets Growth Rate was 23.00% per year.
During the past 3 years, the average Total Assets Growth Rate was 4.20% per year.
During the past 5 years, the average Total Assets Growth Rate was 6.50% per year.
During the past 10 years, the average Total Assets Growth Rate was 18.00% per year.
During the past 13 years, Cogstate's highest 3-Year average Total Assets Growth Rate was 79.40%. The lowest was 4.20%. And the median was 20.20%.
Total Assets is connected with ROA %. Cogstate's annualizedROA % for the quarter that ended in Dec. 2025 was 13.56%. Total Assets is also linked to Revenue through Asset Turnover. Cogstate's Asset Turnover for the quarter that ended in Dec. 2025 was 0.39.
Note:
The Net Income data used here is two times the semi-annual (Dec. 2025) data.
In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.
Total Assets is linked to total revenue through Asset Turnover.
Cogstate's Asset Turnover for the quarter that ended in Dec. 2025 is
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.
Cogstate Total Assets Related Terms
Cogstate Total Assets Historical Data
* Premium members only.
The historical data trend for Cogstate's Total Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.
Cogstate's Total Assets for the fiscal year that ended in Jun. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cogstate (FRA:C4B) has a Total Assets of €58.08 Mil as of Dec. 2025. The total amount of assets as recorded on a company's balance sheet. View historical data on Cogstate and its competitors.
Is Cogstate's Total Assets too high?
Cogstate's current Total Assets is €58.08 Mil. Overall, Cogstate has a GF Score™ of 69/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Cogstate's Total Assets compare to VEEV and BTSG?
Cogstate's Total Assets of €58.08 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Assets for a Healthcare Providers & Services company?
A good Total Assets depends on the Healthcare Providers & Services industry context. However, Total Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Assets mean?
A high Total Assets can signal that a stock is expensive relative to its fundamentals. The total amount of assets as recorded on a company's balance sheet. View historical data on Cogstate and its competitors. Cogstate's current Total Assets is €58.08 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cogstate stock overvalued right now?
Based on GuruFocus' analysis, Cogstate (FRA:C4B) is currently considered Modestly Overvalued. The stock's GF Value™ is €1.35, compared to a current price of €1.68 — trading 24.4% above its estimated fair value. The current Total Assets is €58.08 Mil. Cogstate's overall GF Score™ is 69/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Assets calculated?
Total Assets is calculated from a company's financial statements. For Cogstate (FRA:C4B), the current Total Assets is €58.08 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cogstate (FRA:C4B) Overvalued in 2026?
Based on GuruFocus' analysis, Cogstate stock appears to be overvalued.
The current stock price of €1.68 is trading 24.4% above its estimated GF Value™ of €1.35.
GuruFocus considers Cogstate to be Modestly Overvalued.
Key valuation signals for FRA:C4B:
Total Assets: €58.08 Mil
GF Value™: €1.35 vs. price of €1.68 (24.4% above fair value)
No single metric tells the full story. See the FRA:C4B stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cogstate Ltd is a cognitive science company. The principal activity of the group is the Creation, validation, and commercialisation of digital brain health assessments; and the Design and provision of quality assurance services in clinical trials, focused on the administration, scoring, and recording of conventional brain health assessments and reporting. Its operating segment includes Clinical Trials, Healthcare, and Administration. The company generates maximum revenue from the Clinical Trials segment. In the clinical trials segment, technology and services are sold to pharmaceutical and biotechnology companies. The company derives revenue from the sale of licensed software and cognitive testing services.
69GF Score
Get the complete analysis for FRA:C4B
Total Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:C4B has been successfully added to your 
